Inventor · disambiguated record
Michael Ochse
Also filed as: OCHSE MICHAEL
38 granted patents·13 pending applications·227 citations·filing 2005–2024
97Inventor score
Top patents by PatentIndex Score
51 records- 0194US8431604B2Guanidine compounds, and use thereof as binding partners for 5-HT5 receptorsNETZ ASTRID·Filed 2005·Granted Apr 30, 2013·35 cites·12 claims
- 0293US9273068B2Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10AABBOTT GMBH & CO KG·Filed 2012·Granted Mar 1, 2016·25 cites·44 claims
- 0393US8642587B2Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapyLANGE UDO·Filed 2010·Granted Feb 4, 2014·62 cites·19 claims
- 0490US8481576B2Guanidine compounds, and use thereof as binding partners for 5-HT5 receptorsNETZ ASTRID·Filed 2011·Granted Jul 9, 2013·16 cites·12 claims
- 0590US8420670B24-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapyAMBERG WILHELM·Filed 2008·Granted Apr 16, 2013·17 cites·18 claims
- 0688US8653100B2Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapyOCHSE MICHAEL·Filed 2009·Granted Feb 18, 2014·17 cites·20 claims
- 0788US8563617B2Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapyAMBERG WILHELM·Filed 2010·Granted Oct 22, 2013·13 cites·21 claims
- 0887US9828381B2Substituted pyrazolopyrimidines and method of useABBVIE DEUTSCHLAND·Filed 2016·Granted Nov 28, 2017·3 cites·14 claims
- 0986US8686002B2Heterocyclic compounds and their use as binding partners for 5-HT5 receptorsAMBERG WILHELM·Filed 2006·Granted Apr 1, 2014·5 cites·29 claims
- 1084US10556914B2Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of useABBVIE INC·Filed 2019·Granted Feb 11, 2020·4 cites·16 claims
- 1183US9938269B2Inhibitor compounds of phosphodiesterase type 10AGENESTE HERVE·Filed 2012·Granted Apr 10, 2018·7 cites·33 claims
- 1280US10556907B2Fused heterocyclic compounds as S1P modulatorsABBVIE INC·Filed 2016·Granted Feb 11, 2020·5 cites·12 claims
- 1375US9790203B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 17, 2017·2 cites·26 claims
- 1475US9200005B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Dec 1, 2015·3 cites·23 claims
- 1574US9388180B2Inhibitor compounds of phosphodiesterase type 10AABBOTT GMBH & CO KG·Filed 2013·Granted Jul 12, 2016·3 cites·37 claims
- 1674US8921406B25-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptorsAMBERG WILHELM·Filed 2006·Granted Dec 30, 2014·1 cites·23 claims
- 1773US9856220B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2016·Granted Jan 2, 2018·1 cites·26 claims
- 1872US9096619B2Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Aug 4, 2015·1 cites·20 claims
- 1971US8957089B2Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Feb 17, 2015·1 cites·15 claims
- 2071US2025296917A1Spiro-cyclic amine derivatives as s1p modulatorsABBVIE DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 2169US9475808B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2015·Granted Oct 25, 2016·1 cites·33 claims
- 2269US9163019B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Oct 20, 2015·1 cites·26 claims
- 2368US8846743B2Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapyPOHLKI FRAUKE·Filed 2011·Granted Sep 30, 2014·1 cites·19 claims
- 2467US8877794B2Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyPOHLKI FRAUKE·Filed 2011·Granted Nov 4, 2014·1 cites·18 claims
- 2566US9051280B2Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapyLANGE UDO·Filed 2012·Granted Jun 9, 2015·1 cites·20 claims
- 2666US8883839B2Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapyPOHLKI FRAUKE·Filed 2011·Granted Nov 11, 2014·1 cites·19 claims
- 2762US2022169620A1Spiro-cyclic amine derivatives as s1p modulatorsABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 2861US2015183770A15-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptorsABBVIE DEUTSCHLAND·Filed 2014·Application pending·0 cites
- 2959US2014221371A1Heterocyclic compounds and their use as binding partners for 5-ht5 receptorsABBVIE DEUTSCHLAND·Filed 2013·Application pending·0 cites
- 3058US9475782B2Guanidine compounds, and use thereof as binding partners for 5-HT5 receptorsABBVIE DEUTSCHLAND·Filed 2012·Granted Oct 25, 2016·0 cites·3 claims
- 3157US9067871B2Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Jun 30, 2015·0 cites·6 claims
- 3256US10155770B2Substituted pyrazolopyrimidines and method of useABBVIE DEUTSCHLAND·Filed 2017·Granted Dec 18, 2018·0 cites·17 claims
- 3355US10308610B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2017·Granted Jun 4, 2019·0 cites·22 claims
- 3455US2017037016A1Guanidine compounds and use thereof as binding partners for 5-ht5 receptorsABBVIE DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 3554US9238619B2Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2014·Granted Jan 19, 2016·0 cites·26 claims
- 3654US9227930B2Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapyABBOTT LAB·Filed 2014·Granted Jan 5, 2016·0 cites·19 claims
- 3754US2013116241A1Novel inhibitor compounds of phosphodiesterase type 10aABBOTT GMBH & CO KG·Filed 2012·Application pending·0 cites
- 3854US2013116229A1Novel inhibitor compounds of phosphodiesterase type 10aABBOTT GMBH & CO KG·Filed 2012·Application pending·0 cites
- 3950US2018222905A1Novel inhibitor compounds of phosphodiesterase type 10aABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 4049US9657034B2Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitorsABBVIE DEUTSCHLAND·Filed 2016·Granted May 23, 2017·0 cites·61 claims
- 4149US2018030033A1Novel inhibitor compounds of phosphodiesterase type 10aABBVIE INC·Filed 2017·Application pending·0 cites
- 4246US9045459B2Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyPOHLKI FRAUKE·Filed 2011·Granted Jun 2, 2015·0 cites·10 claims
- 4345US9296697B2Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptorsAMBERG WILHELM·Filed 2006·Granted Mar 29, 2016·0 cites·22 claims
- 4445US2017073353A1Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of useABBVIE INC·Filed 2016·Application pending·0 cites
- 4543US9464085B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 11, 2016·0 cites·33 claims
- 4641US9365512B2Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Jun 14, 2016·0 cites·20 claims
- 4741US9309200B2Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapyAMBERG WILHELM·Filed 2012·Granted Apr 12, 2016·0 cites·23 claims
- 4841US2015158842A1Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2015·Application pending·0 cites
- 4939US2021147381A11,2,3,4-substituted quinoline compounds as sip modulatorsABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 5037US10280159B2Fused (hetero)cyclic compounds as S1P modulatorsABBVIE DEUTSCHLAND·Filed 2016·Granted May 7, 2019·0 cites·19 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael Ochse files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →